ABSTRACT
Sarcoidosis is a multisystem granulomatous disease of unknown cause.
Although all organs of the body may be affected by sarcoidosis (1), the lung is most commonly involved (2). At least two-thirds of patients with pulmon-
ary sarcoidosis have resolution or stabilization of their disease, and this
often occurs within two years (3-8). However, permanent severe pulmonary
dysfunction may occur and accounts for most morbidity and mortality (9-
11). Seventy-five percent of all deaths related to sarcoidosis are from
advanced pulmonary involvement (12). A moderate proportion of these
deaths may be related to pulmonary hypertension (13,14).
